DK1853232T3 - Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse - Google Patents

Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse

Info

Publication number
DK1853232T3
DK1853232T3 DK06708346T DK06708346T DK1853232T3 DK 1853232 T3 DK1853232 T3 DK 1853232T3 DK 06708346 T DK06708346 T DK 06708346T DK 06708346 T DK06708346 T DK 06708346T DK 1853232 T3 DK1853232 T3 DK 1853232T3
Authority
DK
Denmark
Prior art keywords
methods
dosage forms
crystalline form
stable crystalline
bifeprunox mesylate
Prior art date
Application number
DK06708346T
Other languages
English (en)
Inventor
Irene Eijgendaal
Gerrit Klein
Amstel Maria J L Terhorst-Van
Klaas Zwier
Nico Bruins
Hendrikus T Rigter
Eric Gout
Caroline Boon
Vries Michiel H De
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Application granted granted Critical
Publication of DK1853232T3 publication Critical patent/DK1853232T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06708346T 2005-02-18 2006-02-17 Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse DK1853232T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65414905P 2005-02-18 2005-02-18
PCT/EP2006/060055 WO2006087369A1 (en) 2005-02-18 2006-02-17 Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them

Publications (1)

Publication Number Publication Date
DK1853232T3 true DK1853232T3 (da) 2009-12-14

Family

ID=36383746

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06708346T DK1853232T3 (da) 2005-02-18 2006-02-17 Stabil krystallin form af bifeprunox mesylat, doseringsformer deraf og fremgangsmåder for deres anvendelse

Country Status (12)

Country Link
US (1) US7423040B2 (da)
EP (1) EP1853232B1 (da)
AT (1) ATE439831T1 (da)
CA (1) CA2598407A1 (da)
DE (1) DE602006008583D1 (da)
DK (1) DK1853232T3 (da)
ES (1) ES2331487T3 (da)
HR (1) HRP20090569T1 (da)
PL (1) PL1853232T3 (da)
PT (1) PT1853232E (da)
SI (1) SI1853232T1 (da)
WO (1) WO2006087369A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) * 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
US20080132520A1 (en) * 2006-08-31 2008-06-05 Winsemius Antje A Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds
CA2661120A1 (en) * 2006-08-31 2008-03-06 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
US20090068290A1 (en) * 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
US20100119622A1 (en) * 2008-09-15 2010-05-13 Auspex Pharmaceuticals, Inc. 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189612B1 (en) 1984-12-21 1992-11-04 Duphar International Research B.V New pharmaceutical compositions having a psychotropic activity
JP3989554B2 (ja) 1996-03-29 2007-10-10 デユフアー・インターナシヨナル・リサーチ・ベー・ブイ ピペラジンおよびピペリジン化合物
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
CA2310950C (en) 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US8691277B2 (en) 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
ATE417834T1 (de) 2005-08-22 2009-01-15 Solvay Pharm Bv N-oxide als prodrugs von piperazin- und piperidinderivaten

Also Published As

Publication number Publication date
ATE439831T1 (de) 2009-09-15
SI1853232T1 (sl) 2010-01-29
WO2006087369A1 (en) 2006-08-24
EP1853232A1 (en) 2007-11-14
EP1853232B1 (en) 2009-08-19
PL1853232T3 (pl) 2010-01-29
DE602006008583D1 (de) 2009-10-01
HRP20090569T1 (hr) 2009-11-30
ES2331487T3 (es) 2010-01-05
CA2598407A1 (en) 2006-08-24
US7423040B2 (en) 2008-09-09
PT1853232E (pt) 2009-11-12
US20060194812A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
DK2150530T3 (da) Substituerede sulfonamid-derivater
MX2022004937A (es) Inhibidores de las cinasas raf.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20071593L (no) Pyrimidinderivater
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
NO20091299L (no) Substituerte sulfonamidderivater
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
BRPI0513367A (pt) arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
NO20091052L (no) Diaryleterderivater og anvendelser derav
EA201990621A1 (ru) Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения